Calidi Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
CLDI NYSE American 2836 www.calidibio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - Jun 16th, 2026 6:00 am
Calidi Biotherapeutics Announces Investor Webinar on June 9, 2026 - Jun 8th, 2026 6:00 am
Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on June 9 - Jun 5th, 2026 10:00 am
Calidi Biotherapeutics Announces Online Abstract Acceptances at the 2026 ASCO Annual Meeting - May 26th, 2026 6:00 am
Calidi Biotherapeutics Provides Required NYSE American Disclosure - May 22nd, 2026 4:00 pm
Calidi Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Operational Highlights - May 14th, 2026 2:10 pm
Calidi Biotherapeutics Confirms Featured Speaker Presentation Tomorrow at the ASGCT Conference in Boston - May 13th, 2026 6:00 am
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI - Apr 29th, 2026 6:00 am
RedChip's Biotech Virtual Investor Conference Replays Now Available - Apr 21st, 2026 1:00 pm
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - Apr 21st, 2026 6:00 am
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - Apr 20th, 2026 6:00 am
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Apr 15th, 2026 6:00 am
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - Apr 14th, 2026 6:00 am
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Apr 7th, 2026 9:00 am
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - Apr 7th, 2026 6:00 am
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - Apr 2nd, 2026 6:00 am
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - Apr 1st, 2026 6:00 am
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights - Mar 27th, 2026 2:25 pm
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials - Mar 24th, 2026 6:00 am
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing - Mar 12th, 2026 6:00 am